Flipper, I am somewhat confused. If the entire proneural group with its IDH mutants were removed from the trial, what is your estimate of the number of patients remaining in the trial?
Is it possible that many of the patients with the IDH mutated GBM were underrepresented throughout the trial since many in that category had undergone early pseudoprogression and were therefore never allowed into the main trial?
In your opinion has the exclusion of the proneural group resulted in the exclusion of as many as 10% of the original 331 patients? Hopefully the elimination of the proneural GBM group will highlight the efficacy of DCVax-L in the remaining newly defined (bonafide) GBM patients
Market Data 
Markets 
AI
